Evidence map›Paper›PMID 42439805›Full record

ArticleAntimicrobial agents and chemotherapy2026

Marie Sylvianne Rabodoarivelo, Jordana Galizia, Deborah Recchia, Alessandro Stamilla, Michael Dal Molin, Eik Hoffmann, Cyril Gaudin, Maxime Eveque, Dominique Ndjogou, Rebeca Bailo and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Marie Sylvianne Rabodoarivelo *Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.ORCID 0000-0002-4630-5446
Jordana Galizia *Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.ORCID 0000-0001-5029-325X
Deborah RecchiaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy.
Alessandro StamillaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy.
Michael Dal MolinDivision of Infectious Diseases, Department I of Internal Medicine, University of Cologne, Cologne, Germany.ORCID 0000-0002-1587-6692
Eik HoffmannUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204, Centre d'Infection et d'Immunité de Lille (CIIL), Lille, France.ORCID 0000-0003-4224-1091
Cyril GaudinUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204, Centre d'Infection et d'Immunité de Lille (CIIL), Lille, France.
Maxime EvequeUniversity of Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, Lille, France.ORCID 0000-0002-1542-9163
Dominique NdjogouUniversity of Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, Lille, France.
Rebeca BailoDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Albin A M LedingDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Ulrika S H SimonssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Olalla SanzGlobal Health Medicines R&D, GlaxoSmithKline GSK, Tres Cantos, Madrid, Spain.
Elena JiménezGlobal Health Medicines R&D, GlaxoSmithKline GSK, Tres Cantos, Madrid, Spain.
Robert H BatesGlobal Health Medicines R&D, GlaxoSmithKline GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0003-1926-8114
Giulia DegiacomiDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy.ORCID 0000-0002-3626-8311
Ainhoa LucíaDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
Nicolas WillandUniversity of Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, Lille, France.ORCID 0000-0002-0784-0462
Alain BaulardUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204, Centre d'Infection et d'Immunité de Lille (CIIL), Lille, France.ORCID 0000-0002-0150-5241
Jan RybnikerDivision of Infectious Diseases, Department I of Internal Medicine, University of Cologne, Cologne, Germany.ORCID 0000-0001-8351-2690
Maria Rosalia PascaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy.ORCID 0000-0002-8906-4937
Santiago Ramón-GarcíaDepartment of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.ORCID 0000-0002-8480-0325
ERA4TB consortium

Funding

Innovative Medicines Initiatives 2 Joint Undertaking No 853989
6 · The paper itself

Abstract

GSK2556286 (GSK286) is a novel drug candidate with a cholesterol-dependent mode of action that has shown promising

Indexed as

Antitubercular AgentsDiarylquinolinesMycobacterium tuberculosisNitroimidazolesMicrobial Sensitivity TestsAntitubercular AgentsbedaquilineDiarylquinolinesNitroimidazolespretomaniddose-response time-kill assayGSK2556286 (GSK286)pharmacodynamicsregimentuberculosis

Identifiers

PMID42439805
PMCPMC13436017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.